What they are saying: Study on cancer R & D costs is not an accurate representation of marketplace

A recent study published inJAMA Internal Medicine provides flawed and inaccurate estimates of the significant research and development (R&D) investments made by biopharmaceutical companies to develop new cancer treatments and cures for patients. The study focuses on a selective sample of companies that have been successful, ignores significant investments in early stage R&D and relies on inaccurate assumptions regarding industry revenues.
Source: The Catalyst - Category: Pharmaceuticals Tags: Research and Development cancer drug cost Market Distortions Source Type: news